
Smallpox - Pipeline Insight, 2025
Description
DelveInsight’s, “Smallpox - Pipeline Insight, 2025,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Smallpox pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Smallpox: Overview
Smallpox is an acute contagious disease caused by the variola virus, a member of the orthopoxvirus family. It was one of the most devastating diseases known to humanity and caused millions of deaths before it was eradicated. Smallpox is a category A pathogen which are those organisms/biological agents that pose the highest risk to national security and public health because they can be easily disseminated or transmitted from person to person, result in high mortality rates and have the potential for major public health impact, might cause public panic and social disruption, and require special action for public health preparedness.
""Smallpox - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Smallpox pipeline landscape is provided which includes the disease overview and Smallpox treatment guidelines. The assessment part of the report embraces, in depth Smallpox commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Smallpox collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Smallpox report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Smallpox Emerging Drugs
Further product details are provided in the report……..
Smallpox: Therapeutic Assessment
This segment of the report provides insights about the different Smallpox drugs segregated based on following parameters that define the scope of the report, such as:
Smallpox: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Smallpox therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Smallpox drugs.
Smallpox Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Smallpox: Overview
Smallpox is an acute contagious disease caused by the variola virus, a member of the orthopoxvirus family. It was one of the most devastating diseases known to humanity and caused millions of deaths before it was eradicated. Smallpox is a category A pathogen which are those organisms/biological agents that pose the highest risk to national security and public health because they can be easily disseminated or transmitted from person to person, result in high mortality rates and have the potential for major public health impact, might cause public panic and social disruption, and require special action for public health preparedness.
""Smallpox - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Smallpox pipeline landscape is provided which includes the disease overview and Smallpox treatment guidelines. The assessment part of the report embraces, in depth Smallpox commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Smallpox collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Smallpox R&D. The therapies under development are focused on novel approaches to treat/improve Smallpox.
This segment of the Smallpox report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Smallpox Emerging Drugs
- Brincidofovir: Chimerix
- TNX-801: Tonix Pharmaceuticals Holding Corp
Further product details are provided in the report……..
Smallpox: Therapeutic Assessment
This segment of the report provides insights about the different Smallpox drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Smallpox
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Smallpox: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Smallpox therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Smallpox drugs.
Smallpox Report Insights
- Smallpox Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Smallpox drugs?
- How many Smallpox drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Smallpox?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Smallpox therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Smallpox and their status?
- What are the key designations that have been granted to the emerging drugs?
- Chimerix
- BioFactura
- Tonix Pharmaceuticals Holding Corp
- Bavarian Nordic A/S
- ViRAZE
- HK inno.N
- Brincidofovir
- TNX-801
- TNX 1200
- MVA-BN® FREEZE-DRIED
- VIR002
- IN-B002
Table of Contents
40 Pages
- Introduction
- Executive Summary
- Smallpox: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Smallpox – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Smallpox companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Smallpox Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Prergistration)
- Comparative Analysis
- Brincidofovir: Chimerix
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- IN-B002: HK inno.N
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Smallpox Key Companies
- Smallpox Key Products
- Smallpox- Unmet Needs
- Smallpox- Market Drivers and Barriers
- Smallpox- Future Perspectives and Conclusion
- Smallpox Analyst Views
- Smallpox Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.